Susceptibility of intra- and extracellular Mycobacterium avium-intracellulare to cephem antibiotics

Nozawa, Ryushi; Kato, H; Yokota, Takeshi; Sugi, Hideo

doi:10.1128/aac.27.1.132

Cited by 12 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dapsone (164,177) and sulfamethoxazole (168) have minimal antimycobacterial activity in vitro and may contribute to reductions in mycobacteremia in certain patients. In addition, there has been renewed interest in the minimal antimycobacterial activity seen with some beta-lactam antibiotics (78,117,360,491).…”

Section: Therapeutic Agents and Treatmentmentioning

confidence: 99%

The Mycobacterium avium complex.

Inderlied

Kemper

Bermudez

1993

Clinical Microbiology Reviews

View full text Add to dashboard Cite

show abstract

Section: Therapeutic Agents and Treatmentmentioning

confidence: 99%

The Mycobacterium avium complex.

Inderlied

Kemper

Bermudez

1993

Clinical Microbiology Reviews

View full text Add to dashboard Cite

show abstract

“…Dapsone (164, 177) and sulfamethoxazole (168) have minimal antimycobacterial activity in vitro and may contribute to reductions in mycobacteremia in certain patients. In addition, there has been renewed interest in the minimal antimycobacterial activity seen with some beta-lactam antibiotics (78,117,360,491).…”

Section: Therapeutic Agents and Treatmentmentioning

confidence: 99%

The Mycobacterium avium complex

1993

View full text Add to dashboard Cite

Mycobacterium avium complex (MAC) disease emerged early in the epidemic of AIDS as one of the common opportunistic infections afflicting human immunodeficiency virus-infected patients. However, only over the past few years has a consensus developed about its significance to the morbidity and mortality of AIDS. M. avium was well known to mycobacteriologists decades before AIDS, and the MAC was known to cause disease, albeit uncommon, in humans and animals. The early interest in the MAC provided a basis for an explosion of studies over the past 10 years largely in response to the role of the MAC in AIDS opportunistic infection. Molecular techniques have been applied to the epidemiology of MAC disease as well as to a better understanding of the genetics of antimicrobial resistance. The interaction of the MAC with the immune system is complex, and putative MAC virulence factors appear to have a direct effect on the components of cellular immunity, including the regulation of cytokine expression and function. There now is compelling evidence that disseminated MAC disease in humans contributes to both a decrease in the quality of life and survival. Disseminated disease most commonly develops late in the course of AIDS as the CD4 cells are depleted below a critical threshold, but new therapies for prophylaxis and treatment offer considerable promise. These new therapeutic modalities are likely to be useful in the treatment of other forms of MAC disease in patients without AIDS. The laboratory diagnosis of MAC disease has focused on the detection of mycobacteria in the blood and tissues, and although the existing methods are largely adequate, there is need for improvement. Indeed, the successful treatment of MAC disease clearly will require an early and rapid detection of the MAC in clinical specimens long before the establishment of the characteristic overwhelming infection of bone marrow, liver, spleen, and other tissue. Also, a standard method of susceptibility testing is of increasing interest and importance as new effective antimicrobial agents are identified and evaluated. Antimicrobial resistance has already emerged as an important problem, and methods for circumventing resistance that use combination therapies are now being studied.

show abstract

“…More recently, primary cell assays have been used only in confirmatory studies [ 35 ]. In the past, there were numerous researches to investigate drug efficacy in human peripheral blood mononuclear cells (PBMCs) [ 30 , 44 , 45 , 46 , 47 , 48 ]. For studies involving mice, primary bone marrow-derived macrophages have been preferred to other primary cell cultures [ 49 , 50 ], although some older studies have also suggested the use of zymosan A-induced murine peritoneal macrophages [ 51 , 52 ].…”

Section: Static Intracellular Infection Modelsmentioning

confidence: 99%

Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research

et al. 2020

View full text Add to dashboard Cite

Nontuberculous mycobacteria (NTM) represent an increasingly prevalent etiology of soft tissue infections in animals and humans. NTM are widely distributed in the environment and while, for the most part, they behave as saprophytic organisms, in certain situations, they can be pathogenic, so much so that the incidence of NTM infections has surpassed that of Mycobacterium tuberculosis in developed countries. As a result, a growing body of the literature has focused attention on the critical role that drug susceptibility tests and infection models play in the design of appropriate therapeutic strategies against NTM diseases. This paper is an overview of the in vitro and in vivo models of NTM infection employed in the preclinical phase for early drug discovery and vaccine development. It summarizes alternative methods, not fully explored, for the characterization of anti-mycobacterial compounds.

show abstract

Susceptibility of intra- and extracellular Mycobacterium avium-intracellulare to cephem antibiotics

Cited by 12 publications

References 7 publications

The Mycobacterium avium complex.

The Mycobacterium avium complex.

The Mycobacterium avium complex

Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research

Contact Info

Product

Resources

About